Edition:
United Kingdom

People: Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

4.90USD
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
$4.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,929
52-wk High
$7.59
52-wk Low
$2.99

Pedder, Simon 

Dr. Simon C. Pedder, Ph.D., has been appointed as Executive Chairman of the Board of the company. Effective April 15, 2019. he is no longer as Lead Independent Director of the Company. Effective April 15, 2019. He was Director of the Company. Dr. Simon Pedder currently serves as the Chief Business and Strategy Officer, Proprietary Products at Athenex, Inc (NASDAQ: ATNX) , a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for treatment of cancer. Simon has a long career in drug development including recent leadership roles as President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of Hepatitis Franchise at Hoffmann-LaRoche, and Vice President and Head of Drug Development at Shearwater Corporation. Formerly, he was on faculty in the Department of Pharmacology in the College of Medicine at the University of Saskatchewan, where he obtained his Ph.D. in Pharmacology. In addition, Simon obtained a Master of Science in Toxicology from Concordia University, a Bachelor of Science in Environmental Studies from the University of Waterloo, and completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --